ABC.L Regulatory News (ABC)

14 Mar 2008 12:02

ABCAM Plc14 March 2008 For immediate release 14 March 2008 ABCAM PLC ("Abcam" or "the Company") Directors' Share Dealings Cambridge UK, 14 March 2008: Abcam plc announces that the following Directorshave sold, to institutional investors, ordinary shares of 1p each in theCompany: +---------------+-----------+--------------+--------+------------+--------------+| Director | No. of | Date sold | Price | Subsequent |Percentage of |+---------------+-----------+--------------+--------+------------+--------------+| | shares | | per | beneficial | issued share |+---------------+-----------+--------------+--------+------------+--------------+| | sold | | share | holding | capital || | | | | | following |+---------------+-----------+--------------+--------+------------+--------------+| | | | | | sale |+---------------+-----------+--------------+--------+------------+--------------+|Jonathan Milner| 1,000,000 |13 March 2008 | 345p | 8,044,960 | 22.98 |+---------------+-----------+--------------+--------+------------+--------------+| | | | | | |+---------------+-----------+--------------+--------+------------+--------------+|David Cleevely | 500,000 |13 March 2008 | 345p | 4,169,760 | 11.91 |+---------------+-----------+--------------+--------+------------+--------------+| | | | | | |+---------------+-----------+--------------+--------+------------+--------------+|Jim Warwick | 30,000 |13 March 2008 | 345p | 836,200 | 2.39 || | | | | | ||(shares held in| | | | | ||his wife's | | | | | ||name, Jane | | | | | ||Dominey) | | | | | |+---------------+-----------+--------------+--------+------------+--------------+| | | | | | |+---------------+-----------+--------------+--------+------------+--------------+ For the purposes of the Financial Services Authority's Disclosure andTransparency Rules, the total number of ordinary shares of 1p of Abcam in issueon the date of admission will be 35,002,984 with each share holding one votingright. The above figure may be used by shareholders as the denominator for thecalculations by which they will determine if they are required to notify theirinterest in, or a change to their interest in, the Company under the Disclosureand Transparency Rules. For further information please contact: Abcam + 44 (0) 1223 696000 Jonathan Milner, Chief Executive OfficerJeffrey Iliffe, Chief Financial Officer www.abcam.com Numis Securities + 44 (0) 20 7260 1000James Black / Nick Westlake Buchanan Communications + 44 (0) 20 7466 5000 Mark Court / Mary-Jane Johnson / SusannaGale Notes for editors About Abcam plc Abcam is a producer and distributor of research-grade antibodies headquarteredin Cambridge, UK, with offices in Cambridge, Massachusetts, USA and Tokyo,Japan. Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company produces and distributes its own and third partyproduced antibodies to academic and commercial users throughout the world.Product ordering is available through the Company's website www.abcam.com, wherecustomers are also able to access up-to-date and detailed technical productdata sheets. All the antibodies are sold under the Abcam brand name and theCompany's vision is to build the world's largest online resource of high qualityand commercially viable antibodies. Abcam now has an online catalogue of over41,000 products, most of which are antibodies, from over 200 suppliers andemploys 168 staff in its three operating companies. This information is provided by RNS The company news service from the London Stock Exchange